A Phase 3, Open-Label Study Evaluating the Longterm Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis

Grants and Contracts Details

StatusFinished
Effective start/end date6/16/224/3/24

Funding

  • Vertex Pharmaceuticals Inc: $97,400.00